China SXT Pharmaceuticals (SXTC) Competitors $0.32 -0.02 (-5.91%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsShort InterestTrends SXTC vs. CNSP, GTBP, SYRS, HOTH, PPBT, IMCC, ELAB, CANF, AEZS, and BMRAShould you be buying China SXT Pharmaceuticals stock or one of its competitors? The main competitors of China SXT Pharmaceuticals include CNS Pharmaceuticals (CNSP), GT Biopharma (GTBP), Syros Pharmaceuticals (SYRS), Hoth Therapeutics (HOTH), Purple Biotech (PPBT), IM Cannabis (IMCC), Elevai Labs (ELAB), Can-Fite BioPharma (CANF), Aeterna Zentaris (AEZS), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry. China SXT Pharmaceuticals vs. CNS Pharmaceuticals GT Biopharma Syros Pharmaceuticals Hoth Therapeutics Purple Biotech IM Cannabis Elevai Labs Can-Fite BioPharma Aeterna Zentaris Biomerica CNS Pharmaceuticals (NASDAQ:CNSP) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings. Do institutionals and insiders believe in CNSP or SXTC? 14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 0.1% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is CNSP or SXTC more profitable? Company Net Margins Return on Equity Return on Assets CNS PharmaceuticalsN/A N/A -515.32% China SXT Pharmaceuticals N/A N/A N/A Which has higher earnings & valuation, CNSP or SXTC? China SXT Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCNS PharmaceuticalsN/AN/A-$18.85M-$74.970.00China SXT Pharmaceuticals$1.93M0.67-$3.10MN/AN/A Which has more volatility & risk, CNSP or SXTC? CNS Pharmaceuticals has a beta of 2.55, meaning that its share price is 155% more volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Do analysts rate CNSP or SXTC? CNS Pharmaceuticals presently has a consensus price target of $0.50, suggesting a potential upside of 362.96%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than China SXT Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00China SXT Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to CNSP or SXTC? In the previous week, CNS Pharmaceuticals' average media sentiment score of 0.00 equaled China SXT Pharmaceuticals'average media sentiment score. Company Overall Sentiment CNS Pharmaceuticals Neutral China SXT Pharmaceuticals Neutral Does the MarketBeat Community favor CNSP or SXTC? China SXT Pharmaceuticals received 35 more outperform votes than CNS Pharmaceuticals when rated by MarketBeat users. However, 71.21% of users gave CNS Pharmaceuticals an outperform vote while only 61.65% of users gave China SXT Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCNS PharmaceuticalsOutperform Votes4771.21% Underperform Votes1928.79% China SXT PharmaceuticalsOutperform Votes8261.65% Underperform Votes5138.35% SummaryCNS Pharmaceuticals beats China SXT Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get China SXT Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SXTC vs. The Competition Export to ExcelMetricChina SXT PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.38M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E RatioN/A10.5990.0517.18Price / Sales0.67196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.015.094.784.78Net Income-$3.10M$151.83M$120.31M$225.60M7 Day Performance-16.88%-2.14%-1.92%-1.23%1 Month Performance-16.45%-4.56%13.65%0.46%1 Year Performance-82.98%8.87%28.34%15.24% China SXT Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SXTCChina SXT Pharmaceuticals0.1727 of 5 stars$0.32-5.9%N/A-82.5%$1.38M$1.93M0.0090Positive NewsGap UpCNSPCNS Pharmaceuticals1.2211 of 5 stars$0.10-0.9%$0.50+390.2%-99.8%$5.86MN/A0.005Gap DownGTBPGT Biopharma3.6544 of 5 stars$2.59-5.8%$11.00+324.7%-78.3%$5.79MN/A0.008Positive NewsGap UpSYRSSyros Pharmaceuticals4.2571 of 5 stars$0.21+3.4%$3.33+1,455.5%-96.5%$5.75M$9.94M-0.07120Gap UpHOTHHoth Therapeutics2.0095 of 5 stars$0.81flat$3.50+332.1%-30.8%$5.59MN/A-0.614Gap UpPPBTPurple Biotech1.6642 of 5 stars$4.05+5.7%$33.00+714.8%N/A$5.39MN/A-0.4720IMCCIM Cannabis0.0474 of 5 stars$2.40-2.8%N/A+3.4%$5.36M$51.39M-0.72340Gap DownELABElevai Labs0.3441 of 5 stars$2.06-10.0%N/A-99.3%$5.33M$2.45M-0.0318News CoverageGap DownCANFCan-Fite BioPharma1.7922 of 5 stars$1.50-5.1%$14.00+833.3%-30.7%$5.31M$667,000.00-0.888AEZSAeterna ZentarisN/A$2.90flatN/A-68.1%$5.20M$2.37M-0.2020Analyst ForecastBMRABiomerica0.1423 of 5 stars$0.31-1.5%N/A-76.8%$5.20M$5.51M-0.8260Gap Down Related Companies and Tools Related Companies CNS Pharmaceuticals Alternatives GT Biopharma Alternatives Syros Pharmaceuticals Alternatives Hoth Therapeutics Alternatives Purple Biotech Alternatives IM Cannabis Alternatives Elevai Labs Alternatives Can-Fite BioPharma Alternatives Aeterna Zentaris Alternatives Biomerica Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SXTC) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China SXT Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China SXT Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
